ALLK实时信号 | 通过Getagraph.com最大化利润

出售 115743 min ago

@ $1.285

发出时间: 15 Feb 2024 @ 02:34

回报率: -9.73%

上一信号: Feb 14 - 23:47

上一信号: 购买

回报率: 4.47 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	177 165
平均成交量	608 693
市值	102.71M
EPS	$0 ( 2024-03-18 )
下一个收益日期	( $-0.410 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.540
ATR14	$0.00400 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Radford Harlan Baird	Sell	32 142	Common Stock
2024-03-05	Tomasi Adam	Sell	47 392	Common Stock
2024-03-04	Alexander Robert	Sell	70 910	Common Stock
2024-02-16	Radford Harlan Baird	Buy	900 000	Stock Option (Right to buy)
2024-02-16	Lee Chin Hyok	Buy	500 000	Stock Option (Right to buy)

INSIDER POWER
57.98
Last 96 transactions
Buy: 11 461 350 \| Sell: 2 630 713

音量相关性

長: 0.02 (neutral)

短: 0.98 (very strong)

Signal:(77.908) Expect same movement, but be aware

Allakos Inc 相关性

10 最正相关
DSKE	0.963
NAKD	0.963
EXFY	0.962
TCDA	0.961
ALGT	0.958
BNR	0.958
CMBM	0.958
BZFD	0.956
ALRS	0.956
PODD	0.955

10 最负相关
ALTR	-0.957
NVDA	-0.954
GPACU	-0.952
PRDO	-0.95
PESI	-0.95
OHAA	-0.95
RAM	-0.948
CCRC	-0.948
SENEA	-0.946
MMYT	-0.945

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Allakos Inc 相关性 - 货币/商品

-0.04
( neutral )

-0.21
( neutral )

0.00
( neutral )

0.40
( neutral )

Allakos Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-6.14M (0.00 %)
EPS:	$-2.14

FY	2023
营收:	$0
毛利润:	$-6.14M (0.00 %)
EPS:	$-2.14

FY	2022
营收:	$0
毛利润:	$-9.98M (0.00 %)
EPS:	$-5.02

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-5.01

Financial Reports:

No articles found.

Allakos Inc

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.